Insys Therapeutics Inc (INSY) was Reiterated by Piper Jaffray to “Overweight” while Lowering the Price Target of the company shares to $ 28 from a previous price target of $46 . Piper Jaffray advised their investors in a research report released on Apr 11, 2016.
Many Wall Street Analysts have commented on Insys Therapeutics Inc. Shares were Reiterated by Jefferies on Feb 24, 2016 to “Buy” and Lowered the Price Target to $ 23 from a previous price target of $36 .Shares were Reiterated by RBC Capital Mkts on Feb 1, 2016 to “Outperform” and Lowered the Price Target to $ 44 from a previous price target of $49 .
On the company’s financial health, Insys Therapeutics Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Feb 23, 2016. Analyst had a consensus of $0.29. The company had revenue of $91.10 million for the quarter, compared to analysts expectations of $91.04 million. The company’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Insys Therapeutics Inc closed down -3.42 points or -19.37% at $14.24 with 39,39,679 shares getting traded on Monday. Post opening the session at $14.95, the shares hit an intraday low of $13.2 and an intraday high of $15.33 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price. According to the SEC, on Mar 4, 2016, Theodore H Stanley (director) sold 20,000 shares at $18.11 per share price. On Nov 18, 2015, John N Kapoor (CEO) purchased 5,000 shares at $29.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.